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Purpose. Latanoprost has become one of the most widely prescribed topical antihypertensive medications in recent years. Yet there
have been few reports of secondary iris pigment epithelial (IPE) and ciliary body (CB) cyst formation to date and none, to our
knowledge, reported in eyes predisposed to primary angle closure. Methods. We report the first documented case of bilateral IPE
and CB cysts in a hypermetropic patient with prior laser peripheral iridotomies (LPIs) as a rare, delayed side effect of topical
Latanoprost treatment. The cysts subsided with discontinuation of Latanoprost, thereby demonstrating a causal relationship. We
discuss the pathogenesis of such cysts and advocate using of serial ultrasound biomicroscopic (UBM) images to monitor them.
Results and Conclusions. Latanoprost may cause iris pigment epithelial and ciliary body cysts that remain clinically undetected.
In eyes predisposed to angle closure, such cysts may become clinically detectable and masquerade as iris tumours. Prior laser
peripheral iridotomies in these eyes may delay or prevent the detection of these cysts. Ultrasound biomicroscopy (UBM) imaging
is therefore a valuable tool in diagnosing and monitoring these cysts.
1. Introduction
Latanoprost is a prostaglandin-F2-alpha analogue that acts
as an agonist of the prostaglandin-F2-alpha receptor. In
1996, it became the first prostaglandin analogue available
and is currently first-line treatment option for reducing
intraocular pressure (IOP) in ocular hypertension or open-
angle glaucoma.
Despite its widespread use, there have been no reported
cases of secondary ciliary body (CB) cyst formation and
only four reported cases of secondary iris pigment epithelial
(IPE) cyst formation. In addition, cyst formation is not a
listed side effect of the drug in the most recent British
National Formulary [1]. We report the first documented case
of bilateral IPE and CB cysts in a hypermetrope with prior
laser peripheral iridotomies (LPIs) as a delayed side effect of
topical Latanoprost.
2. Case Report
A 62-year-old Caucasian male was being monitored annually
for ocular hypertension, having been referred from his opti-
cian in 2006 with raised intraocular pressures on a routine
eye test. His subjective refraction was +6.50/−1.25 × 25 in
the right eye (OD) and +6.75/−1.00 × 160 in the left eye
(OS). Best-corrected visual acuities (BCVAs) were 6/4 and
6/6 in the right and left eyes, respectively.There was no family
history of glaucoma, and the patient was asthmatic. Initial
gonioscopy had revealed open but narrow, nonoccludable
iridotrabecular angles bilaterally.
Presenting IOPs were 24mmHg and 19mmHg, with
average central corneal thicknesses of 542 (OD) and 555
(OS)microns. Visual fields on theHumphrey 24-2 automated
analyser were normal and cup-to-disc ratios were 0.5 each,
with healthy neuroretinal rim appearances. In April 2011, the
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Figure 1: (a) Predilation and (b) postdilation anterior segment photos of left eye showing large inferotemporal iris cyst at presentation, causing
ectropion uveae and anterior displacement of the iris surface. Four months after stopping topical Latanoprost, the cyst is only evident after
dilation. Note patent peripheral iridotomies (arrow).
patient was noted to have raised IOPs of 34mmHg (OD)
and 30mmHg (OS) with gonioscopically narrow, occludable
iridotrabecular angles likely as a result of an increase in lens
thickness with time. Only the anterior part of the trabecular
meshwork was visible in more than half of the angle, with no
peripheral anterior synechiae in either eye (all parts of the
angle opened fully on indentation gonioscopy in both eyes).
His discs and visual fields remained unchanged.
Primary angle closure (PAC) was diagnosed and he
underwent routine sequential laser peripheral iridotomies
(LPIs). Two months later, IOPs were still raised despite
gonioscopic confirmation of opening of the angles. He was
therefore started on topical Latanoprost at night to good effect
with IOPs lowering to 17mmHg bilaterally. Visual fields and
IOPs remained stable over the next three years, during which
period he underwent a number of routine reviews including
a dilated fundal examination that was normal.
At a routine appointment in November 2014, forty-one
months after commencing Latanoprost, he was noted to
have uveal tissue protruding through the undilated left pupil,
causing anterior displacement of the inferotemporal iris
surface (Figure 1(a)). The right iris appeared unremarkable.
Whilst both eyes were noted to have early lens opacities,
BCVAs remained excellent at 6/5 (OD) and 6/7.5 (OS), and
IOPs remained stable at 18mmHg (OD) and 19mmHg (OS).
There were no signs of uveitis and dilated fundal examination
was unremarkable in both eyes. The smooth dark brown
mass of uveal tissue wasmore pronounced after pupil dilation
(Figure 1(b)).
An ultrasound biomicroscopy (UBM) scan revealedmul-
tiple IPE and ciliary body (CB) cysts at the 3, 6, and 9
o’clock meridians in the left eye with the largest being in
the inferotemporal quadrant. Similar IPE and CB cysts were
detected in the contralateral eye, despite not being evident on
the slit lamp (Figure 2). Axial lengths were 20.18mm (OD)
and 19.93mm (OS), whilst lens thicknesses were 5.17mm
(OD) and 5.05 (OS) mm, resulting in high lens: axial length
ratios of 0.25 in each eye.
The patient was referred to an ocular oncologist who
felt the appearance was in keeping with benign secondary
IPE and CB cysts. Latanoprost was discontinued and Brin-
zolamide commenced. Beta-blockers were avoided given the
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Figure 2: Ultrasound biomicroscopy (UBM) images of (a) right and (b) left eyes showing multiple iris pigment epithelial and ciliary body
cysts in both eyes prior to stopping topical Latanoprost.
patient’s asthmatic status. During subsequent monitoring,
the left iris cyst was noted to gradually decrease in size
and, four months later, was only evident on dilated slit-lamp
examination (Figure 1(b)). At the most recent nine-month
follow-up, the cyst was not visible even after dilation. IOPs
were reasonable at 20mmHg (OD) and 15mmHg (OS) on
topical Brinzolamide three times daily. Visual fields and optic
discs had remained unchanged.
3. Discussion
Iris cysts are a rare side effect of topical Latanoprost treat-
ment. It has been suggested that the increase in uveoscle-
ral outflow caused by PG-F2-alpha analogues such as
Latanoprost contributes to cyst formation by altering aqueous
humour dynamics through the interepithelial space of the
posterior iris [2]. This case suggests that high hypermetropia
may be an additional mechanism by which these cysts
become clinically detectable.
Ours is first reported case of CB cysts occurring together
with the IPE cysts. Only two previous cases had UBM imag-
ing to assess the anterior segment’s morphological changes
caused by the IPE cysts, neither of which were in eyes
with PAC and neither of which reported additional CB cyst
formation. None of the previous cases documented axial
lengths or relative lens sizes.
Four previously reported cases of IPE cysts secondary to
Latanoprost have taken between 5 weeks and 18 months to
develop [3–6]. Our patient was a high hypermetrope with
thick lenses and occludable angles who had LPIs before
Latanoprost had been commenced. He developed clinically
detectable IPE and CB cysts more than 3 years later, far
longer than those previously reported. This delay could be
explained if the prior LPIs prevented a relative pupil block
and forward bowing of the iris, allowing the cysts to gradually
enlarge undetected. In addition, the IOP lowering effect of
Latanoprost itself could explain why the cysts were able to
enlarge to such an extent over a long period of time, without
causing any IOP increase.
We postulate that had our patient not had prior LPIs, the
formation of clinically detectable IPE and CB cysts would
have been far earlier due to a further increase in sectoral
appositional angle closure caused by the developing cysts.
This may give rise to a “pseudoplateau iris” syndrome, as has
been previously reported [7]. Although a possibility, it is not
known whether these sectoral secondary IPE and CB cysts
could potentiate angle closure in eyes with narrow angles.
4. Conclusions
In the absence of a prospective study utilising serial ante-
rior segment UBM imaging, the true incidence of iris and
ciliary body cyst formation due to Latanoprost and other
topical prostaglandin analogues is unknown. Ours is the first
reported case of bilateral UBM-confirmed secondary ciliary
body and IPE cyst formation due to Latanoprost, with the
cysts in the fellow eye only being detected by UBM imaging.
We therefore propose that both IPE and CB cysts for-
mations are rare side effects of Latanoprost treatment. In
eyes anatomically at risk of PAC, the development of these
cysts may potentiate sectoral angle closure and we therefore
recommend UBM as the imaging modality of choice to help
diagnose and monitor these cysts.
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The patient has consented to the publication of this case
report. This report, however, does not contain any personal
information that could lead to the identification of the
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